![]() All information you provide in this site will be governed by our Privacy Policy. Your data will be processed in compliance with applicable privacy laws including the EU General Data Protection Regulation. and Oracle Corp.) solely for the purposes of data hosting, phone calls and QIAGEN email distribution. QIAGEN may transfer your personal information to our CRM system (hosted by, Inc. QIAGEN may also use your personal information for internal business and marketing purposes that may include regular promotional offers, news, invitations via email or telephone.The information will not be sold to any third party. Subject to your consent given above, by clicking on "submit," QIAGEN may use your personal information to communicate with you regarding this topic. ![]() QIAGEN Digital Insights may extend these licenses should the need arise. Researchers actively involved in SARS-CoV-2 genomics and bioinformatics in government or academic laboratories are entitled to a ‘temporary 14-day license’ for QIAGEN CLC Genomics Workbench Premium which allows them a license to use the software at no cost. ![]() Latest news from QIAGEN on the fight against coronavirus.GISAID Initiative for rapid and open access to influenza virus data.GitHub resource maintained by Duncan MacCannell (CDC Office of Advanced Molecular Detection).Overly exuberant innate immune response to SARS-CoV-2 infection.Type 2 and interferon inflammation strongly regulate SARS-CoV-2 related gene expression in the airway epithelium.Focusing on the unfolded protein response and autophagy-related pathways to reposition common approved drugs against COVID-19.Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease.Genomic and protein structure modelling analysis depicts the origin and pathogenicity of 2019-nCoV.A novel coronavirus from patients with pneumonia in China, 2019.Ultrarapid diagnosis, microscope imaging, genome sequencing, and culture isolation of SARS-CoV-2.Focusing on pathways to reposition common approved drugs against COVID-19.LY6E impairs coronavirus fusion and confers immune control of viral disease.Identifying SARS-CoV-2 related coronaviruses in Malayan pangolins.Proteomic and metabolomic characterization of COVID-19 sera.Genomic evidence for reinfection with SARS-CoV-2: a case study.A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm.Publications using QIAGEN IPA and/or QIAGEN CLC Genomics to study COVID-19 RNA transcript discovery using QIAGEN CLC Genomics Workbench.Comparative analysis of whole genomes using QIAGEN CLC Workbenches.De novo transcriptome assembly using QIAGEN CLC Genomics Workbench.Microbial data analysis for uncorrected long reads with QIAGEN CLC Genomics Workbench.De novo assembly of Oxford Nanopore MinION reads with QIAGEN CLC Genomics Workbench.QIAGEN CLC Genomics Workbench 20 – scalable desktop software for NGS data analysis (January 28, 2020).Bacterial strain typing and genomics characterization of multi-drug resistance with QIAGEN CLC Genomics Workbench (March 9, 2020).Scaling your bioinformatics with QIAGEN CLC Genomics Server and Cloud Engine (March 25, 2020).Bioinformatics analysis of Nanopore sequencing data for SARS-CoV-2 (April 2, 2020).Using QIAGEN Digital Insights to research coronavirus fusion and immune control (May 6, 2020).QIAGEN CLC User Group Meeting (May 26 and 27, 2020) Watch the on-demand presentations from this online event, including talks on QIAGEN CLC core and advanced capabilities, use cases from KOLs and a discussion on SARS-CoV-2 analysis using CLC Genomics Workbench.QIAGEN CLC Genomics resources for microbial and viral genomics Webinars * Offer not available in combination with other offers. To help them accelerate impactful insights, with every purchase of this kit they receive 25% off any 1-year subscription to QIAGEN CLC Genomics bioinformatics software. In addition, we have a special offer* for labs that purchase the QIAseq SARS-CoV-2 Primer Panel Kit (96). To support these efforts, QIAGEN Digital Insights is offering laboratories involved in COVID-19 research and the global pandemic response free 14-day temporary licenses to QIAGEN CLC Genomics Workbench Premium and QIAGEN IPA. QIAGEN Ingenuity Pathway Analysis (IPA) is used by thousands of researchers worldwide and cited extensively in studies of the host response to viruses. QIAGEN CLC Genomics has also been critical for many labs on the front lines of the COVID-19 pandemic involved in sequencing the SARS-CoV-2 virus. QIAGEN CLC Genomics Workbench software is used by hundreds of microbiology and virology labs around the world for basic research and infectious disease epidemiology.
0 Comments
Leave a Reply. |